Concepedia

Jeffrey M. Witkin

JM

155

Publications

7.2K

Citations

48

H-Index

1976

Active since

Affiliations

Eli Lilly (United States)(Current)

National Institute on Drug Abuse

National Institutes of Health

University of Wisconsin–Milwaukee

Walter Reed Army Institute of Research

Jeffrey M. Witkin is an author at Eli Lilly (United States) specializing in medicine, neuropharmacology, and neuroscience.

ORCID

Top concepts

Publications per year

1976–2024

155

Publications

155

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

Eleni T. Tzavara, Richard J. Davis, Kenneth W. Perry et al. · British Journal of Pharmacology · 2003 · 269 citations · Full text

Allosteric modulation of the muscarinic M <sub>4</sub> receptor as an approach to treating schizophrenia

Wai‐Yee Chan, David L. McKinzie, Suchira Bose et al. · Proceedings of the National Academy of Sciences · 2008 · 233 citations · Full text

Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac)

Per Svenningsson, Eleni T. Tzavara, Jeffrey M. Witkin et al. · Proceedings of the National Academy of Sciences · 2002 · 229 citations · Full text

Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections.

Jeffrey M. Witkin, David E. Nichols, Philip Terry et al. · Journal of Pharmacology and Experimental Therapeutics · 1991 · 178 citations

Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice

Xia Li, Anne B. Need, Melvyn Baez et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 160 citations

Rows per page

1–5 of 155